Introduction
============

Pulmonary arterial hypertension is a progressive disease characterized by increased pulmonary vascular resistance due to vasoconstriction and remodeling (reviewed in [@B51]; [@B34]). The pathologic abnormalities in vascular lesions include intimal hyperplasia, medial thickness, plexiform lesions, and thrombosis *in situ* ([@B21]; [@B48]; [@B56]), which are caused by increased migration and proliferation of smooth muscle cells and adventitial fibroblasts, abnormal endothelial cell proliferation, and impaired apoptosis. Although several treatment options have become available and have significantly improved morbidity and mortality, the 5-year survival rate for PAH patients remains at \~60% ([@B26]). Early diagnosis and accurate prognostic stratification of patients at baseline and during follow-up are important to ensure optimal therapeutic strategies ([@B50]). Thus, finding novel genes involved in the pathogenesis of PAH could provide a better understanding of the pathophysiological mechanisms and suggest novel therapeutic approaches for the disease ([@B17]; [@B31]).

Transcriptome analysis could represent a new frontier in the search for novel biomarkers and/or therapeutic targets in various diseases, because it facilitates the identification of panels of genes specifically dysregulated in affected tissues ([@B42], [@B44]; [@B46]; [@B45]; [@B53]). A number of transcriptome analyses of PAH patients and PAH animal models have been performed and the data have been deposited in a public database ([@B5]). These include data derived from two cohorts of human patients ([@B39]; [@B68]; [@B69]); a rat PAH model caused by treatment with the vascular endothelial growth factor receptor inhibitor SU5416 under conditions of hypoxia ([@B38]); a mouse PAH model caused by overexpression of Fra-2 ([@B6]), a causative gene for systemic sclerosis; a mouse PAH model caused by schistosomiasis ([@B16]); a rat model caused by left heart disease ([@B20]); a rat model caused by *Pneumocystis* infection ([@B59]); and a mouse PAH model caused by deletion of cavin-1 ([@B60]). In this study, we sought to identify genes commonly dysregulated in PAH in both human and rodent models. Therefore, we selected for analysis both cohorts of human PAH patients ([@B39]; [@B68]; [@B69]); two mouse models caused by schistosomiasis ([@B16]) and Fra-2 overexpression ([@B6]), which were selected because schistosomiasis and connective tissue diseases such as systemic sclerosis are major causes of PAH ([@B57]); and a rat PAH model caused by SU5416 and hypoxia ([@B38]), which we included in this study because we have successfully employed this PAH model ([@B48]; [@B56]). We acknowledg that our transcriptome analysis of these datasets may not detect genes involved in other common causes of PAH, such as left heart and/or lung diseases.

We performed a comparative transcriptome analysis of the two human and three rodent PAH datasets and found that coiled-coil domain containing 80 (CCDC80) may be a novel biomarker and therapeutic target in PAH. We validated the function of CCDC80 as it relates to PAH using zebrafish. Many transgenic zebrafish lines expressing fluorescent proteins in various cells have been developed and are available through public resources, enabling multiple approaches to *in vivo* imaging of the relevant target cells in zebrafish larvae ([@B43]). Specific genes can also be knocked out using clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 systems ([@B4]). Thus, when used in combination with advanced technologies for genetic manipulation, *in vivo* imaging of the zebrafish ventral artery, which supplies blood to the gill arches where gas exchange occurs by diffusion ([@B22]), may be a useful tool to characterize the function of genes related to PAH. Our *in vivo* validation using the zebrafish model revealed that *ccdc80* knockout increased the diameter of the ventral artery. Finally, we examined Ccdc80 expression in a rat PAH model and found increased staining in the hypertrophied media and adventitia of the pre-acinar pulmonary arteries (PAs) and in the thickened intima, media, and adventitia of the obstructed intra-acinar PAs.

Materials and Methods {#s1}
=====================

Ethics Statement
----------------

This study was carried out in strict accordance with Japanese law \[The Humane Treatment and Management of Animals (2014), Standards Relating to the Care and Management of Laboratory Animals and Relief of Pain (2013), and the Guidelines for Proper Conduct of Animal Experiments (2006) ([@B55]; [@B36], [@B37])\]. All efforts were made to minimize animal suffering. Mie University Institutional Animal Care and Use Committee guidelines state that no approval is required for experiments using zebrafish.

Compounds
---------

Sodium nitroprusside (SNP) was obtained from Millipore (Billerica, MA, USA) and dissolved in 0.3x Danieau's solution (19.3 mM NaCl, 0.23 mM KCl, 0.13 mM MgSO~4~, 0.2 mM Ca(NO~3~)~2~, 1.7 mM HEPES, pH 7.2) immediately before use in experiments. KT5823 was obtained from Tocris (Bristol, UK). Stock solutions of KT5823 were prepared by dissolving in dimethyl sulfoxide (Nacalai Tesque, Kyoto, Japan). [L]{.smallcaps}-NAME was obtained from Dojin Chemicals (Kumamoto, Japan). 2-Phenoxyethanol was obtained from Wako Chemicals (Osaka, Japan).

Comparative Transcriptome Analysis
----------------------------------

To compare DEGs in human PAH and rodent models of PAH of different etiologies, we analyzed five lung transcriptome datasets. GSE8078 was derived from a rat PAH model caused by treatment with the VEGF receptor inhibitor SU5416 under conditions of hypoxia ([@B38]). Adult male rats received a single subcutaneous injection of SU-5416 and were housed under hypoxic condition for 3.5 weeks. mRNA was isolated from whole lung tissue of the PAH rats (*n* = 3) and the control rats (*n* = 4). GSE51222 was derived from a mouse PAH model caused by overexpression of Fra-2 ([@B6]), and mRNA was isolated from the lung homogenates of 8-week-old transgenic mice (*n* = 3) and wild-type littermate controls (*n* = 3). GSE48936 was derived from a mouse PAH model caused by schistosomiasis ([@B16]). Female mice received an intraperitoneal injection of *Schistosoma mansoni* eggs followed 2 weeks later by challenge with *S. mansoni* eggs injected via the tail vein. One week later, lung mRNA was isolated from injected (*n* = 3) and uninjected (*n* = 3) mice. GSE24988 and GSE53408 were derived from human PAH patients ([@B39]; [@B68]; [@B69]). For our study, we compared the transcriptomes of patients with pulmonary fibrosis without PAH (*n* = 22) and with intermittent PAH (*n* = 45) in GSE24988 and controls (*n* = 11) and patients with PAH (*n* = 12) in GSE53408.

The raw data were normalized using the packages "affy" ([@B14]) for GSE8078, "limma" ([@B52]) for GSE51222, and "oligo" ([@B10]) for GSE48936, GSE24988, and GSE53408 in Bioconductor ([@B15]). Probes with reliable signals were selected and subjected to RankProd ([@B7]) analysis to identify DEGs in the PAH groups compared with control groups in each dataset. False discovery rates were set at 20% for the rodent PAH models, 10% for one human cohort (GSE24988), and 5% for the second human cohort (GSE53408). The gene symbols of the DEGs were converted to the human orthologs using Life Science Knowledge Bank (World Fusion, Tokyo, Japan), and UniProt IDs were added using the ID mapping tool ([@B63]). The lists of DEGs are shown in Supplementary Tables [S1-1](#SM3){ref-type="supplementary-material"}--[S1-5](#SM3){ref-type="supplementary-material"}. The DEGs common to all five PAH transcriptome datasets are shown in **Table [1](#T1){ref-type="table"}**.

###### 

Differentially expressed genes common to the five PAH transcriptome datasets.

                      SU5416/hypoxia GSE8078   Fra-2 TG GSE51222   Schistosomiasis GSE48936   Human PAH GSE24988   Human PAH GSE53408                                   
  ---------- -------- ------------------------ ------------------- -------------------------- -------------------- -------------------- ------ -------- ------ -------- ------
  *AGR2*     095994   1.17                     0.01                0.87                       0.01                 1.26                 0.03   0.35     0.00   1.19     0.00
  *CCDC80*   Q76M96   0.71                     0.14                0.61                       0.06                 1.02                 0.08   0.17     0.00   1.15     0.00
  *GZMA*     P12544   --0.61                   0.06                --4.18                     0.00                 --0.77               0.17   --0.16   0.04   --0.71   0.00
  *SMAD6*    043541   --1.12                   0.00                --0.51                     0.16                 --1.18               0.03   --0.03   0.10   --0.96   0.00

Weighted Gene Co-Expression Network Analysis
--------------------------------------------

To identify molecular interactions between genes potentially related to PAH, we performed weighted gene co-expression network analysis (WGCNA). WGCNA can organize transcriptomic data into networks based on underlying expression relationships, such as correlations, to elucidate novel connections between genes ([@B46]). Expression data for 40 genes commonly dysregulated in the five PAH transcriptome datasets (Supplementary Table [S2](#SM4){ref-type="supplementary-material"}) were subjected to WGCNA ([@B28]) in Bioconductor ([@B15]). The 40 genes were clustered into three modules of correlated genes: the first contained *CCDC80*, the second contained both *SMAD6* and *GZMA*, and the third contained *AGR2*. The gene networks in modules 1, 2, and 3 were identified using thresholds of 0.05, 0.25, and 0.02, respectively.

Zebrafish Strains
-----------------

We used two lines of zebrafish: a Tg (fli1:EGFP) line ([@B29]) obtained from Zebrafish International Resource Center (Eugene, OR, USA) ([@B65]) and an albino line ([@B25]) obtained from the Max Planck Institute for Developmental Biology (Tübingen, Germany). Zebrafish were bred and maintained according to previously described methods ([@B67]; [@B41]). Briefly, zebrafish were raised at 28.5°C ± 0.5°C with a 14 h/10 h light/dark cycle. Embryos were obtained by natural mating and cultured in 0.3x Danieau's solution until 6 dpf, at which time they were used for the *in vivo* imaging analyses or were processed for quantitative polymerase chain reaction (qPCR).

Knockout of ccdc80 in Zebrafish
-------------------------------

Knockout of ccdc80 in zebrafish was performed by the ready-to-use CRISPR/Cas9 method ([@B27]). CRISPR RNA (crRNA) targeting a 5′-AAGCAGCCCGACCGATAAAC-3′ sequence in the ccdc80 genome and trans-activating crRNA (tracrRNA; [@B27]) were obtained from FASMAC (Kanagawa, Japan). Recombinant Cas9 protein was obtained from Toolgen (Seoul, South Korea). In brief, crRNA, tracrRNA, and Cas9 protein were dissolved in sterilized water at concentrations of 250, 1000, and 1000 ng/μl, respectively, and stored at -80°C until required. For microinjection, the crRNA, tracrRNA, Cas9 protein, and a lissamine-labeled control morpholino with no known target gene (Gene Tools, Philomath, OR, USA) were mixed in Yamamoto's Ringer's solution (0.75% NaCl, 0.02% KCl, 0.02% CaCl~2~, 0.002% NaHCO~3~) to final concentrations of 100 ng/μl, 100 ng/μl, 400 ng/μl, and 50 nM, respectively. The solution was injected into 1--4-cell-stage zebrafish embryos derived from the Tg (fli1: EGFP) line or albino lines. At 1 dpf, the embryos exhibiting bright lissamine fluorescence were selected and maintained until 6 dpf. At 6 dpf, the selected zebrafish were used for *in vivo* imaging of the ventral artery or were processed for qPCR. After completion of the *in vivo* imaging experiments, genomic DNA was extracted from the zebrafish by incubation in 50 μl of lysis buffer (10 mM Tris-HCl, pH 8.0, 0.1 mM EDTA, 0.2% Triton X-100, 200 μg/ml proteinase K) at 55°C overnight, followed by incubation at 99°C for 10 min. The solution was then placed at 4°C and used as the template for PCR. To detect the crRNA-induced mutations, a short fragment of the ccdc80 gene encompassing the crRNA target sites was amplified from the genomic DNA using ccdc80_gF1 and ccdc80_gR1 primers and QuickTaq (Toyobo, Osaka, Japan). PCR cycling conditions were: 94°C for 2 min followed by 40 cycles of 94°C for 30 s, 60°C for 30 s, and 68°C for 30 s. The PCR products were electrophoresed on 10% poly-acrylamide gel (Wako Chemicals) and visualized by ethidium bromide staining. The crRNA, tracrRNA, and PCR primer sequences are shown in Supplementary Table [S3](#SM5){ref-type="supplementary-material"}.

*In Vivo* Imaging of the Ventral Artery of Tg (fli1:EGFP) Zebrafish
-------------------------------------------------------------------

Zebrafish at 6 dpf were incubated with or without SNP (1--10 mM) and/or [L]{.smallcaps}-NAME (10 mM) in the presence or absence of the protein kinase G (PKG) inhibitor KT5823 (1 μM). Zebrafish were exposed to the chemicals for 1 h for experiments examining the SNP dose-response and the effect of KT5823, and for 2 h for the experiments examining the effect of [L]{.smallcaps}-NAME with or without SNP. The zebrafish were then transferred onto glass slides, placed on their backs, and immobilized by covering with a few drops of 3% low-melting point agarose solution. The ventral artery was visualized using an epifluorescence microscope (SMZ25, Nikon, Tokyo, Japan) with GFP-B filters, and images were recorded at 100 frames/s for 5 s. Quantitative assessment of the ventral artery diameter was performed using Volocity (Perkin Elmer, Cambridge, MA, USA). Briefly, the time-lapse images were used to generate M-mode tracings at the level immediately below the first branches of the ventral artery. The ventral artery diameters were then measured manually. The lengths of ventral artery (from the level immediately below the bifurcation to 1st afferent branchial artery to the level immediately above arterial bulb) were also measured manually.

qPCR Analysis
-------------

Total RNA was extracted from control or ccdc80-KO albino zebrafish at 6 dpf using an RNAqueous Micro Kit (Takara, Kyoto, Japan) according to the manufacturer's protocol. RNA concentrations were determined using a NanoDrop spectrophotometer (Thermo Scientific, Waltham, MA, USA), and aliquots were reverse transcribed using an iScript Select cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). qPCR was performed using an ABI Prism 7300 (Life Technologies, Carlsbad, CA, USA) with SYBR Green Realtime PCR Master Mix Plus (Toyobo). The thermal cycling conditions were: 95°C for 1 min followed by 40 cycles of 95°C for 15 s, 60°C for 15 s, and 72°C for 45 s. We measured the expression of collagen type I alpha 1 (*col1a1*), secreted frizzled-related protein 2 (*sfrp2*), endothelin-1 (*edn1*), and glyceraldehyde-3-phosphate dehydrogenase (*gapdh*) mRNA. The data were normalized to *gapdh* mRNA levels to correct for variability in the initial template concentration and the conversion efficiency of the reverse transcription reaction. The primer sequences are shown in Supplementary Table [S3](#SM5){ref-type="supplementary-material"}.

Immunohistochemistry
--------------------

Immunohistochemistry was performed as described previously on lungs excised from control rats or rats with PAH caused by SU5416/hypoxia ([@B48]; [@B56]). Briefly, sections of paraffin-embedded lung tissue were deparaffinized and hydrated. Epitope retrieval was performed by boiling the sections in citrate buffer (0.01 M, pH 6.0), and endogenous peroxidase activity was quenched with 0.3% hydrogen peroxide in methanol. Sections were then blocked in 5% normal goat serum and incubated overnight at 4°C with a rabbit polyclonal antibody to Ccdc80 (ab75881, Abcam, Cambridge, UK) or a mouse monoclonal antibody to α-smooth muscle actin (α-SMA, 1A4; Sigma, St. Louis, MO, USA). Antibody binding was amplified with streptavidin-biotin (LSAB2 kit, Dako, Kyoto, Japan), and sections were incubated with 3,3′-diaminobenzidine substrate and counterstained with hematoxylin. For the negative controls, sections were incubated with rabbit or mouse immunoglobulin instead of the primary antibody (**Figures [5D,H](#F5){ref-type="fig"}**). The localization and intensity of staining were assessed by two independent examiners (HS and EZ) who were blinded to the rat treatment group.

Statistical Analysis
--------------------

Statistical analysis was performed using Prism 6 (GraphPad, La Jolla, CA, USA). Group means were compared by unpaired *t*-test for two groups and by analysis of variance (ANOVA) for four groups. Alpha was set at 0.05, and Dunnett's multiple comparisons test was used for *post hoc* analysis when significant effects were found by ANOVA. Data are shown as the mean ± standard error (SEM).

Results
=======

Identification of DEGs Common to the Five Mammalian PAH Transcriptome Datasets
------------------------------------------------------------------------------

We performed comparative transcriptome analysis to identify genes dysregulated in the three rodent PAH models and two cohorts of human PAH patients. We identified 228, 379, 850, 1598, and 4260 DEGs in PAH caused by SU5416/hypoxia, Fra-2 TG, schistosomiasis, human PAH cohort 1, and human PAH cohort 2, respectively, compared with the relevant controls (Supplementary Tables [S1-1](#SM3){ref-type="supplementary-material"}--[S1-5](#SM3){ref-type="supplementary-material"}). A Venn diagram showing unique and shared DEGs is shown in **Figure [1](#F1){ref-type="fig"}**. Four DEGs were either upregulated or downregulated in all five datasets (**Table [1](#T1){ref-type="table"}**). Expression of coiled-coil domain containing 80 (*CCDC80*) and anterior gradient 2 (*AGR2*) was significantly increased in the five PAH transcriptome datasets, whereas SMAD family member 6 (*SMAD6*) and granzyme A (*GZMA*) were significantly decreased in all datasets. These results suggest that the four DEGs may be novel biomarkers in PAH.

![**Venn diagram of DEGs in the five PAH transcriptome datasets.** Transcriptome data from a rat PAH model caused by treatment with the VEGFR inhibitor SU5416 and hypoxia (GSE8078); a mouse PAH model caused by overexpression of Fra-2, a causative gene for systemic sclerosis (GSE51222); a mouse PAH model caused by schistosomiasis (GSE48936); and two cohorts of human PAH patients (GSE24988 and GSE53408) were downloaded from a public database (GEO). Genes that were differentially expressed in the PAH and control groups of each dataset were identified as described in the methods. The numbers of DEGss unique to each transcriptome dataset and shared between datasets are shown.](fphar-07-00142-g001){#F1}

Identification of Gene Networks Dysregulated in PAH
---------------------------------------------------

To identify molecular networks common to the genes dysregulated in PAH, we used WGCNA. We calculated the coefficient of variation (CV) of the normalized probe intensity for each gene in each transcriptome dataset and then sorted the genes in descending order by CV. The top 3000 genes in each PAH transcriptome dataset were selected (Supplementary Tables [S1-1](#SM3){ref-type="supplementary-material"}--[S1-5](#SM3){ref-type="supplementary-material"}). A total of 40 genes were common to the five sets of 3000 genes (Supplementary Tables [S2-3--S2-6](#SM4){ref-type="supplementary-material"}) and were subjected to WGCNA. **Figure [2](#F2){ref-type="fig"}** shows the networks assigned to the genes dysregulated in PAH by WGCNA. The four genes identified in **Table [1](#T1){ref-type="table"}** (*CCDC80*, *AGR2*, *SMAD6*, and *GZMA*) are included in the three networks identified by WGCNA (**Figure [2](#F2){ref-type="fig"}**). *CCDC80* is connected to collagen type I alpha 1 (*COL1A1*), secreted frizzled-related protein 2 (*SFRP2*), and insulin-like growth factor 1 (*IGF1*). *SMAD6* is connected to endothelin 1 (*EDN1*) and *GZMA*. *COL1A1*, *IGF1*, and *EDN1* have all been associated with the pathophysiology of PAH ([@B47]; [@B51]; [@B32]; [@B34]), supporting our hypothesis that *CCDC80*, *SMAD6*, and *GZMA* may be involved in the disease pathophysiology.

![**Networks among the genes dysregulated in PAH identified by WGCNA.** The coefficient of variation (CV) of the normalized probe intensity for each gene in each transcriptome dataset was calculated, and the genes were sorted in descending order by CV. Of the top 3000 genes in each dataset, 40 genes were common to all five datasets and were subjected to WGCNA. The genes were clustered into three modules and the networks identified in these modules are shown. *CCDC80*, *AGR2*, *SMAD6*, and *GZMA*, which were significantly dysregulated in all five PAH transcriptome datasets, are shown in boxes.](fphar-07-00142-g002){#F2}

Nitric Oxide Induces Ventral Artery Dilation Through Activation of PKG in Zebrafish
-----------------------------------------------------------------------------------

Although comparative transcriptome analysis identified *CCDC80* as a novel gene in PAH, the function of *CCDC80* in the vasculature is largely unknown. To analyze the function of *ccdc80 in vivo*, we first established a functionally relevant PAH model using Tg (fli1:EGFP) zebrafish, which express EGFP in vascular endothelial cells ([@B29]). For this, we examined the effect of nitric oxide (NO) on the ventral artery. Treatment of zebrafish with the NO donor SNP dose-dependently dilated the ventral artery (Supplementary Figure [S1A](#SM1){ref-type="supplementary-material"}), and this was significantly attenuated by co-treatment with KT5823, a specific inhibitor of PKG (Supplementary Figure [S1B](#SM1){ref-type="supplementary-material"}), indicating that the effects of NO on the ventral artery diameter were regulated though PKG. Inhibition of NO synthase with the specific inhibitor [L]{.smallcaps}-NAME significantly decreased the ventral artery diameter when added alone and reversed the artery dilation caused by SNP treatment (**Figure [3](#F3){ref-type="fig"}**). The length of ventral artery was not significantly different between the groups. These results indicate that, like the pulmonary artery in mammals, the ventral artery in zebrafish is regulated through NO--PKG signaling.

![**The zebrafish ventral artery diameter is increased by a NO donor and decreased by a NO synthase inhibitor. (A)** *In vivo* imaging of the ventral artery of Tg (fli1:EGFP) zebrafish at 6 dpf. Zebrafish were incubated with or without 10 mM Sodium nitroprusside (SNP) and/or 10 mM [L]{.smallcaps}-NAME for 2 h and then placed on microscope slides on their backs. The ventral artery was imaged under a fluorescent microscope at 100 frames/s for 5 s. The image stack projections and time-lapse imaging traces at the level of the ventral artery (dotted lines) are shown. Scale bars, 100 μm. **(B)** The diameter of the ventral artery was increased and decreased by zebrafish treatment with SNP and [L]{.smallcaps}-NAME, respectively, relative to untreated zebrafish. The ventral artery diameter of zebrafish co-treated with SNP and [L]{.smallcaps}-NAME was not significantly different from that of control zebrafish. The ventral artery diameters were measured using time-lapse imaging. *N* = 5 for each group. \**p* \< 0.05 vs control. **(C)** The length of ventral artery in zebrafish treated with SNP and/or [L]{.smallcaps}-NAME was not significantly different compared to that in untreated zebrafish. *N* = 5 for each group.](fphar-07-00142-g003){#F3}

*ccdc80* Knockout Increases Ventral Artery Diameter and Decreases Expression of *col1a1* and *edn1* in Zebrafish
----------------------------------------------------------------------------------------------------------------

We next determined whether *ccdc80* plays a role in controlling ventral artery diameter in zebrafish. Previous reports have demonstrated that *ccdc80* is expressed in the cardiovascular system in zebrafish ([@B8]; [@B12]). Using the CRISPR/Cas9 system ([@B2]; [@B27]), we knocked out *ccdc80* in Tg (fli1:EGFP) zebrafish (Supplementary Figure [S2](#SM2){ref-type="supplementary-material"}). When these animals were examined by fluorescence microscopy, we observed that the ventral artery diameter in *ccdc80*-KO zebrafish was significantly larger than that of control zebrafish (**Figure [4A](#F4){ref-type="fig"}**). The length of ventral artery was not significantly different between the groups, verifying that the wider diameter of the ventral artery in *ccdc80*-KO zebrafish was not related to the length of the ventral artery in the KO group (**Figure [4A](#F4){ref-type="fig"}**).

![**Knockout of *ccdc80* causes ventral artery dilation and decreases *col1a1* and *edn1* expression in zebrafish. (A)** *In vivo* imaging of the ventral artery of control and ccdc80 knockout Tg (fli1:EGFP) zebrafish at 6 dpf. Zebrafish were placed on slides on their backs, and the ventral artery was imaged under a fluorescence microscope at 100 frames/s for 5 s. Image stack projections and time-lapse imaging traces at the level of the ventral artery (dotted lines) are shown. Bar, 100 μm. The ventral artery diameter of the *ccdc80* knockout zebrafish was significantly larger than that of control, whereas the length of ventral artery was not significantly different between groups. The upper right bar graph shows quantification of ventral artery diameters measured using time-lapse imaging. The lower right bar graph shows quantification of ventral artery lengths. *N* = 6 or 9 for the control and ccdc80 knockout groups, respectively. \**p* \< 0.05 vs. control. **(B)** qPCR analysis of *col1a1*, *sfrp2*, and *edn1* mRNA levels in control and *ccdc80* knockout zebrafish at 6 dpf. Expression of *col1a1*, *sfrp2*, and *edn1* was normalized to that of *gapdh*. *N* = 8 per group. \**p* \< 0.05 vs. control groups.](fphar-07-00142-g004){#F4}

Because WGCNA identified *COL1A1* and *SFRP2* in the *CCDC80* network (**Figure [2](#F2){ref-type="fig"}**), we compared the whole-body expression of *col1a1* and *sfrp2* mRNA in control and *ccdc80*-KO zebrafish. As shown in **Figure [4B](#F4){ref-type="fig"}**, the expression of *col1a1* mRNA was significantly lower in ccdc80-KO animals compared with the controls, whereas *srfp2* mRNA levels were unchanged. *COL1A1* expression is increased by overexpression of *EDN1* ([@B19]) and decreased by inhibition of *EDN1* synthesis ([@B11]); therefore, we also measured the effect of *ccdc80* deletion on *edn1* expression. We found that *edn1* mRNA levels were significantly lower in *ccdc80*-KO zebrafish compared with the control animals (**Figure [4B](#F4){ref-type="fig"}**). These results suggest that CCDC80 may regulate the pulmonary artery tone by modulating endothelin-1-induced collagen expression.

Ccdc80 Expression Is Increased in the Pulmonary Vascular Lesion in a Rat PAH Model
----------------------------------------------------------------------------------

To establish the significance of our findings for PAH pathology, we performed immunohistochemical staining of Ccdc80 protein in the lung tissues of control rats and rats with PAH caused by SU5416 and hypoxia. Ccdc80 was not readily detected in the PAs of control rats (**Figures [5A,E](#F5){ref-type="fig"}**), but there was intense immunoreactivity in the hypertrophied media and adventitia of the pre-acinar PAs (**Figure [5B](#F5){ref-type="fig"}**) and in the thickened intima, media, and adventitia of the obstructed intra-acinar PAs (**Figure [5F](#F5){ref-type="fig"}**) in the PAH rat. The Ccdc80 immunoreactivity was localized in the α-SMA--positive cells in the PA media but not in the intima or adventitia (**Figures [5C,G](#F5){ref-type="fig"}**).

![**Expression of Ccdc80 is increased in the lungs of rats with PAH. (A--H)** Representative photomicrographs of pulmonary arteries (PAs) from control rats **(A** and **E)** or rats with PAH induced by SU5416 /hypoxia **(B--D** and **F--H)**. Serial cross-sectional views of pre-acinar PA **(A--D)** and intra-acinar PA **(E--H)** immunostained for Ccdc80 and α-smooth muscle actin (α-SMA). Scale bars, 50 μm. Original magnification (×400).](fphar-07-00142-g005){#F5}

Discussion
==========

Involvement of *CCDC80*, *SMAD6*, *AGR2*, and *GZMA* in PAH
-----------------------------------------------------------

We demonstrated that expression of *CCDC80*, *SMAD6*, *AGR2*, and *GZMA* was significantly dysregulated in two cohorts of human PAH patients ([@B39]; [@B68]; [@B69]) and in three rodent PAH models caused by: (i) treatment with a VEGF receptor inhibitor under conditions of hypoxia ([@B38]); (ii) overexpression of Fra-2, a causative gene for systemic sclerosis ([@B6]); and (iii) schistosomiasis ([@B16]).

CCDC80, which was significantly upregulated in the five PAH transcriptome datasets, is a 950-amino acid secreted protein that binds to ECM proteins, including glycosaminoglycans, and promotes cell adhesion ([@B33]). Interestingly, human steroid-sensitive gene 1 (SSG1), which is identical to the 530-amino acid amino-terminal sequence of human CCDC80 protein, is highly expressed in cardiovascular systems and is phosphorylated by PKG ([@B66]). These studies suggest that *CCDC80* may regulate vascular function via the ECM and PKG signaling. Consistent with this, we demonstrated that knockout of *ccdc80* in zebrafish caused dilation of the ventral artery and decreased the expression of *col1a1*. We also found that pharmacological inhibition of PKG significantly attenuated the effect of *ccdc80* knockout on the zebrafish ventral artery (data not shown). Collectively, these findings point to a possible role for *CCDC80* in the pathogenesis of PAH (discussed later).

*SMAD6*, a member of the SMAD family of TGFβ signaling regulators ([@B30]), was also downregulated in all five PAH transcriptome datasets. SMAD6 has been shown to negatively regulate TGFβ signaling through the TGFβ-activated kinase (TAK1)--mitogen-activated protein kinase (MAPK) pathway ([@B23]). Heterozygous mutations in the type II receptor for bone morphogenetic protein (*BMPR2*), which underlie the majority of the inherited and familial forms of PAH ([@B17]), stimulate the TGFβ--TAK1--MAPK pathway ([@B40]). These studies suggest that reduced expression of SMAD6 may increase TGFβ--TAK1--MAPK pathway activity, similar to the effects of BMPR2 mutation. Because inhibition of the TGFβ--TAK1--MAPK pathway rescues abnormal proliferation and apoptosis of pulmonary artery smooth muscle cells isolated from *BMPR2* mutant mice ([@B40]), normalizing the decrease in *SMAD6* expression may be therapeutic in PAH.

The expression of *AGR2* was significantly increased in the five PAH transcriptome datasets. AGR2 has been proposed to be involved in development, tissue regeneration, and cancer metastasis ([@B9]). AGR2 can bind to α-dystroglycan, which regulates the ECM and interaction with integrins ([@B13]). Thus, the increase in *AGR2* expression may be related to the dysregulated ECM observed in PAH.

*GZMA* was significantly downregulated in all five PAH transcriptome datasets. GZMA is a member of the granzyme family of proteins, which are important mediators of cell death induced by immune cells ([@B18]). Previous work has shown that TGFβ decreases *GZMA* expression and inhibits its function in cytotoxic T cells ([@B61]). Dysregulation of cytotoxic T cells has been reported in PAH ([@B62]; [@B54]), raising the possibility that the decrease in *GZMA* expression in PAH may be related to the dysregulation of cytotoxic T cells.

In addition to these observations, the expression levels and/or activities of CCDC80, AGR2, and GZMA in human plasma have been related to various pathological states ([@B1]; [@B24]; [@B35]). It may therefore be worthwhile to perform similar measurements of these proteins in the plasma of human PAH patients and determine whether their levels and/or activities correlate with the clinical stages of PAH.

CCDC80 May Regulate Vascular Tone by Modulating Endothelin-1--induced Collagen Expression
-----------------------------------------------------------------------------------------

In this study, we demonstrated that knockout of *ccdc80* in zebrafish caused dilation of the ventral artery and decreased the expression of both *edn1* and *col1a1*. We also showed that Ccdc80 immunoreactivity was increased in the hypertrophied media and adventitia of the pre-acinar PAs and in the thickened intima, media, and adventitia of the obstructed intra-acinar PAs in a rat PAH model.

The expression of *CCDC80* was correlated with fibrillin-1 whose expression is induced by TGFβ ([@B58]), suggesting that it may be induced by TGFβ signaling. TGFβ signaling is activated in familial PAH caused by mutation of *BMPR2* and in syndromic PAH caused by systemic sclerosis or schistosomiasis ([@B64]; [@B3]). In various models, PAH is ameliorated by blockade of TGFβ signaling through diverse mechanisms, including administration of neutralizing antibodies, antisense nucleotides, or TGFβ receptor kinase inhibitors, and by gene transfer of inhibitory SMAD ([@B64]; [@B3]). TGFβ signaling regulates vascular tone, including that of PAs, by regulating the expression of vasodilators such as NO and vasoconstrictors such as endothelin-1 ([@B49]). These studies suggest that expression of *CCDC80* may positively correlate with TGFβ signaling, leading to decreased NO and increased endothelin-1 levels. Further studies using both *in vitro* and *in vivo* approaches are required to fully elucidate the functions of CCDC80 in the pathophysiology of PAH and to examine its potential as a marker and/or a therapeutic target in PAH.
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DEGs

:   differentially expressed genes

dpf

:   days post-fertilization

ECM

:   extracellular matrix.

[L]{.smallcaps}-NAME

:   *N*-omega-nitro-[L]{.smallcaps}-arginine methyl ester

PAH

:   pulmonary artery hypertension

PKG

:   cGMP-dependent protein kinase

SNP

:   sodium nitroprusside.
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